Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIMULATION-01 low-dose neoadjuvant radiotherapy with chemotherapy and tislelizumab in locally advanced esophageal squamous cell carcinoma
ChiCTR2400084438Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (3 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and Pathologic complete response rate. Started Apr 2024; status: completed.
02
Drugs
tislelizumabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400084438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084438.